Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. de Masson A, et al. Among authors: orvain c. Lancet. 2023 Jun 10;401(10392):1941-1950. doi: 10.1016/S0140-6736(23)00329-X. Epub 2023 Apr 24. Lancet. 2023. PMID: 37105210
Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study.
Orvain C, Luque Paz D, Dobo I, Cottin L, Le Calvez G, Chauveau A, Mercier M, Farhi J, Boyer F, Ianotto JC, Guibourg B, Rousselet MC, Zandecki M, Ifrah N, Hunault-Berger M, Ugo V, Genevieve F. Orvain C, et al. Ann Hematol. 2016 Oct;95(11):1819-23. doi: 10.1007/s00277-016-2784-x. Epub 2016 Sep 1. Ann Hematol. 2016. PMID: 27582015
Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.
Cottin L, Riou J, Orvain C, Ianotto JC, Boyer F, Renard M, Truchan-Graczyk M, Murati A, Jouanneau-Courville R, Allangba O, Mansier O, Burroni B, Rousselet MC, Quintin-Roué I, Martin A, Sadot-Lebouvier S, Delneste Y, Chrétien JM, Hunault-Berger M, Blanchet O, Lippert E, Ugo V, Luque Paz D. Cottin L, et al. Among authors: orvain c. Br J Haematol. 2020 Mar;188(6):935-944. doi: 10.1111/bjh.16276. Epub 2019 Nov 11. Br J Haematol. 2020. PMID: 31710700 Free article.
Different number of circulating CD34 + cells in essential thrombocythemia, prefibrotic/early primary myelofibrosis, and overt primary myelofibrosis.
Luque Paz D, Cottin L, Lippert E, Robin JB, Bescond C, Genevieve F, Boyer F, Quintin-Roue I, Rousselet MC, Burroni B, Hunault-Berger M, Ugo V, Ianotto JC, Orvain C. Luque Paz D, et al. Among authors: orvain c. Ann Hematol. 2022 Apr;101(4):893-896. doi: 10.1007/s00277-021-04672-z. Epub 2021 Oct 5. Ann Hematol. 2022. PMID: 34611719 No abstract available.
Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Le Bourgeois A, Labopin M, Leclerc M, de Latour RP, Bourhis JH, Ceballos P, Orvain C, Wallet HL, Bilger K, Blaise D, Rubio MT, Guillaume T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Le Bourgeois A, et al. Among authors: orvain c. Oncotarget. 2018 Nov 27;9(93):36603-36612. doi: 10.18632/oncotarget.26391. eCollection 2018 Nov 27. Oncotarget. 2018. PMID: 30564300 Free PMC article.
Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial.
Tournilhac O, Le Garff-Tavernier M, Nguyen Quoc S, Forcade E, Chevallier P, Legrand-Izadifar F, Laurent Damaj G, Michonneau D, Tomowiak C, Borel C, Orvain C, Turlure P, Redjou R, Guillerm G, Vincent L, Simand C, Lemal R, Quiney C, Combes P, Pereira B, Calvet L, Cabrespine A, Bay JO, Leblond V, Dhédin N, Organization Filo FIL, De Moelle Et de Thérapie Cellulaire Sfgm-Tc SFG. Tournilhac O, et al. Among authors: orvain c. Haematologica. 2021 Jul 1;106(7):1867-1875. doi: 10.3324/haematol.2019.239566. Haematologica. 2021. PMID: 32527951 Free PMC article.
Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups.
Robin M, Porcher R, Orvain C, Bay JO, Barraco F, Huynh A, Charbonnier A, Forcade E, Chantepie S, Bulabois C, Yakoub-Agha I, Detrait M, Michonneau D, Turlure P, Raus N, Boyer F, Suarez F, Vincent L, Guyen SN, Cornillon J, Villate A, Dupriez B, Cassinat B, Rolland V, Schlageter MH, Socié G, Kiladjian JJ. Robin M, et al. Among authors: orvain c. Bone Marrow Transplant. 2021 Aug;56(8):1888-1899. doi: 10.1038/s41409-021-01252-7. Epub 2021 Mar 25. Bone Marrow Transplant. 2021. PMID: 33767402 Free PMC article. Clinical Trial.
126 results